News
News Center
2023-02-07
Jiuzhitang Maker has achieved ISO9001, ISO14001, and ISO45001 international standard certifications.
Jiuzhitang Maker has been awarded the ISO 9001, ISO 14001, and ISO 45001 international certifications.
+
2023-02-07
Clinical Trial Recruitment: 45 Patients With Ischemic Stroke
On January 12, 2021, China's first Phase I/IIa clinical trial (ASSIST) using imported stem cells to treat ischemic stroke—initiated by Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as "Jiuzhitang Maker")—officially kicked off. To date, Phase I has progressed smoothly, and the company is now recruiting 45 voluntary participants with ischemic stroke to join the Phase IIa trial.
+
2023-02-01
Parkinson's disease is one of the most prevalent neurodegenerative disorders, and developing long-term, effective new clinical treatments to improve the quality of life for patients remains a critical challenge as societies continue to age. After years of intensive basic research, stem cell therapy has gradually matured in recent years and is now moving toward clinical translation.
+
2023-01-17
As the stem-cell innovation division under Jiuzhitang Group, Jiuzhitang Maker has consistently drawn significant attention from industry insiders. After several years of growth, what does Jiuzhitang Maker look like today? Here are a few recent highlights and major developments at Jiuzhitang Maker!
+
2023-01-09
The Regulations stipulate that cell and gene therapies currently undergoing clinical trials for life-threatening diseases with no effective treatment options—provided medical analysis indicates potential benefits outweighing risks, ethical requirements are met, and after review according to national guidelines and with informed consent obtained—may be extended to other patients with identical conditions who are ineligible to participate in the drug’s clinical trials, under the framework of expanded access programs conducted at the medical institutions where the trials are taking place.
+
2022-12-21
On December 14, 2022, the Management Committee of the China (Tianjin) Pilot Free Trade Zone released the "Implementation Plan for Building the China (Tianjin) Pilot Free Trade Zone's Linked Innovation Demonstration Base (Gene and Cell Therapy)" on its "Government Information Disclosure" platform. The plan explicitly states: "Promote the standardized clinical application of cell therapy products, and under controllable risk conditions, prioritize support for autologous cell therapies that involve minimal manipulation—particularly those technologies targeting diseases currently lacking effective treatments but demonstrably proven clinically beneficial."
+
2022-12-01
Jiuzhitang Maker once again listed as a Beijing-based SME specializing in science and technology.
Recently, in accordance with the provisions of the "Evaluation Measures for Technology-Based Small and Medium-Sized Enterprises" (Guo Ke Fa Zheng [2017] No. 115) and the "Guidelines for Evaluation Services of Technology-Based SMEs" (Guo Ke Huo Zi [2022] No. 67), Jiuzhitang Maker has successfully passed the certification process and has once again been officially listed among Beijing's ninth batch of technology-based SMEs for 2022.
+
2022-11-18
Recently, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. has once again been recognized as a National High-Tech Enterprise, earning the prestigious "National High-Tech Enterprise" certificate.
+
2022-11-10
This action plan aims to further boost Shanghai's innovation in cell therapy technology and its industrial development, accelerate the establishment of a globally recognized hub for biopharmaceutical innovation, and strive to build a world-class biopharmaceutical industry cluster.
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy